GSK stock: company announces potential USD 750 million multiple myeloma deal
Published on 10/06/2026 at 18:01 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
GSK stock is in focus after GSK plc announced an agreement on September 15, 2026, to acquire a potential trispecific T-cell engager from Chimagen Biosciences for development in multiple myeloma. The program is expected to enter Phase I trials in 2027, according to the GSK release.
Potential value of up to USD 750 million
Under the agreement, GSK will pay an upfront fee for full global rights to the T-cell engager program. Chimagen may also receive development and commercial milestone payments, bringing the agreement's total potential value to up to USD 750 million. The transaction remains subject to customary closing conditions, the company said in its September 15, 2026, announcement.
Focus on multiple myeloma
GSK said the trispecific asset is designed to bind to T cells while targeting two tumor-associated antigens. The company plans to develop and commercialize the program as part of its blood-cancer portfolio.
